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Optimizing Pediatric Dosing Recommendations and
Treatment Management of Antiretroviral Drugs Using
Therapeutic Drug Monitoring Data in Children Living With
HIV
Hylke Waalewijn, Msc,* Anna Turkova, PhD,†‡ Natella Rakhmanina, PhD,§¶║
Tim R. Cressey, PhD,**††‡‡ Martina Penazzato, PhD,§§ Angela Colbers, PhD,* and
David M. Burger, PhD,* on behalf of the Pediatric Antiretroviral Working Group (PAWG)
Introduction: This review summarizes the current dosing recom-
mendations for antiretroviral (ARV) drugs in the international
pediatric guidelines of the World Health Organization (WHO), US
Department of Health and Human Services (DHHS), and Pediatric
European Network for Treatment of AIDS (PENTA), and evaluates
the research that informed these approaches. We further explore the
role of data generated through therapeutic drug monitoring in
optimizing the dosing of ARVs in children.
Methods: A PubMed search was conducted for the literature on ARV
dosing published in English. In addition, the registration documentation
of European Medicines Agency and the US Food and Drug Adminis-
tration for currently used ARVs and studies referenced by the WHO,
DHHS, and EMA guidelines were screened. Resulting publications were
screened for papers containing data on the area under the concentration–
time curve, trough concentration, and peak concentration. Studies with
enrolled participants with a median or mean age of $18 years were
excluded. No restriction on publishing date was applied.
Discussion and conclusion: Pediatric ARV dosing is frequently
based on data obtained from small studies and is often simplified to
facilitate dosing in the context of a public health approach.
Pharmacokinetic parameters of pediatric ARVs are subject to high
interpatient variation and this leads to a potential risk of underdosing
or overdosing when drugs are used in real life. To ensure optimal use
of ARVs and validate dosing recommendations for children, it is
essential to monitor ARV dosing more thoroughly with larger
sample sizes and to include diverse subpopulations. Therapeutic
drug monitoring data generated in children, where available and
affordable, have the potential to enhance our understanding of the
appropriateness of simplified pediatric dosing strategies recommen-
ded using a public health approach and to uncover suboptimal dosing
or other unanticipated issues postmarketing, further facilitating the
ultimate goal of optimizing pediatric ARV treatment.
Key Words: pediatric, drug dosing, therapeutic drug monitoring,
HIV, antiretroviral therapy
(Ther Drug Monit 2019;41:431–443)
INTRODUCTION
An estimated 1.8 million children younger than 15
years are living with HIV worldwide. The majority are living
in low- and middle-income countries (LMICs).1 The use of
combination antiretroviral therapy for the treatment of pedi-
atric HIV infection has markedly reduced mortality among
children and adolescents infected with HIV.2,3 Early initiation
of antiretroviral treatment (ART) assures maximal suppres-
sion of HIV replication, reduces the viral reservoir, and helps
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to preserve immunologic function allowing for normal growth
and development in pediatric patients.4–6 Therefore, all cur-
rent guidelines recommend to start ART in children living
with HIV as early as possible, regardless of disease progres-
sion or immunologic status.7 Currently, ART for children
consists of a combination of 3 drugs from at least 2 different
classes of antiretrovirals (ARVs): 2 nucleotide or nucleoside
reverse transcriptase inhibitors (NRTIs) combined with a third
agent, a boosted HIV protease inhibitor (PI), a nonnucleoside
reverse transcriptase inhibitor (NNRTI), or an integrase strand
transfer inhibitor (InSTI). Each class of ARVs targets differ-
ent steps of the viral replication cycle.
Optimal ART successfully suppresses viral replication
without causing side effects. This is achieved by administering
the correct dose to ensure safe and therapeutic plasma concen-
trations. Ideally, a dose of a drug provides drug levels in the
target range in all patients, regardless of age and weight, which
is challenging to achieve across the pediatric age continuum.
Historically, the development and implementation of
pediatric ART has been slowed by the lack of evidence from
safety and dose-finding trials for child-appropriate ARV
dosages and formulations already approved in adults. First,
the availability of pediatric formulations for young children is
a major barrier for drug development. Second, until recently,
a recommended approach was to conduct the dose-finding
studies in a staggered way from older to younger children,
which led to a substantial delay for drug development in
children. Only 25% of ARVs licensed for adults by regulatory
agencies such as the European Medicines Agency (EMA) and
the US Food and Drug Administration (FDA) are approved
for treating children younger than 2 years.8 For children liv-
ing in a LMIC, availability of these drugs is further hampered
by the issues of cost and procurement as well as the challeng-
ing administration and storage requirement of some drugs.
Furthermore, recent data indicate significant rise in viral drug
resistance to currently used NNRTIs among children, which
is rapidly rising because of acquisition of the resistant viral
strains from their mothers, selection of drug resistance as
a result of exposure to maternal ARVs or postnatal prophy-
laxis, as well as suboptimal dosing and poor adherence.9
Newer ARVs are not widely available for children, and there-
fore, therapy options are limited.
Based on the mechanism of action of ARV drugs on
viral replication, the same exposure–response or
pharmacokinetic–pharmacodynamic (PK–PD) relationship
can be assumed for all age groups.10 Therefore, provided PK
exposures can be achieved similar to adults; PK and safety
trials in children are considered sufficient to support regula-
tory approval and use of ARVs in children.10
The absorption, distribution, metabolism, and excretion
of drugs in neonates, infants, and children are all affected by
changes in body size and maturation processes.11–15 Although
knowledge and study methods in pediatric pharmacology
have been improving, and requirements for pediatric dose–
finding studies for ARV drugs have become more stringent,
pediatric dosing of the majority of currently used ARV drugs
is still based on the empirical or weight-based scaling of adult
doses.16 Maturation and development in organ function of
children creates changes in drug PK, which make scaling
unpredictable, especially for children younger than 2 years.17
Population PK (PopPK) modeling can be used to
approximate the effect of maturation factors on drug PK in
children, but without data from children, modeling involves
extrapolating from other populations and assumes equivalent PK
processes in the intended population. When data in children are
available, population modeling can be used to provide insight
into the causes of PK variability within the pediatric population.
Apart from the right dose, formulations for children
should be “child-friendly” to enable children to take them.
Therefore, pediatric formulations primarily involve liquids or
low-dose dispersible formulations, which are easy to swallow
and allow for gradual dosing alterations when a child is grow-
ing. Liquid formulations, however, have excipients that can
be toxic to newborns, for example, high alcohol and propyl-
ene glycol content in liquid lopinavir/ritonavir.18 They require
administrations of larger volumes and have more challenging
storage and transport requirements (eg, cold chain and refrig-
eration). Solid preparations are generally significantly easier
to handle and procure. Hence, preference is given to pediatric
dispersible and solid preparations globally.19
International guidelines have been developed and are
regularly updated using latest research results to guide
clinicians on specific ARVs, formulations, and dosing for
children living with HIV. The 3 guidelines that are most
widely used are from the World Health Organization (WHO),
US Department of Health and Human Services (DHHS), and
Pediatric European Network for Treatment of AIDS
(PENTA).7,20–22 Although stringent regulatory drug approval
agencies such as the FDA and EMA base their licensing
generally on the same information, they do not overlap com-
pletely in their age indication and dosing guidance. As
a result, European and American guidelines are not always
aligned on some key points.7,20–22 Until recently, the EMA
and FDA recommended a dose stratified by age and calcu-
lated by multiplying a drug dose in milligram by the body
surface area (BSA) or weight, necessitating a calculation. To
simplify this approach, the WHO introduced weight-band
dosing to support a public health approach and to promote
scale up of pediatric ART. Weight-band dosing, however, is
not without challenges. Dosing within the given weight band
is static and therefore children on the extreme ends of the
weight band might have higher or lower drug exposure rela-
tive to the target levels, which may affect toxicity or efficacy.
In settings where therapeutic drug monitoring (TDM) is
available, it is used to make individual dose adjustments after
examining the actual drug concentration achieved.23 More
recent ARVs have broader therapeutic windows with
improved benefit/risk ratios and reduced intersubject variabil-
ity; thus, the need for TDM of these drugs is currently limited
to certain clinical scenarios. However, because larger interin-
dividual variations in plasma concentrations are seen in chil-
dren and this population is more vulnerable to drug-related
adverse events, clinicians may opt to use TDM in children for
clinical management when dosing uncertainties arise.23 Drug-
level results can also indicate nonadherence and can be used
by health care providers to initiate additional interventions to
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help those children struggling with maintaining drug adher-
ence; however, simplified, cheaper assays are needed to move
this testing outside of research settings and highly resourced
facilities.24
To fully explore the value and potential use of TDM for
validation of recommended dosing, we reviewed the evidence
base for currently recommended dosing of different ARVs
used in first-, second-, and third-line regimens. This review
identifies knowledge gaps that, if addressed, could help
improve pediatric ARVs dosing and, in turn, pediatric HIV
treatment outcomes. We focus on the agents for which plasma
PK parameters are used for dose-finding, and therefore,
nucleoside (and nucleotide) reverse transcriptase inhibitors
(NRTIs) are covered only briefly.
METHODS
We described the current pediatric dosing recommenda-
tions outlined in 3 international guidelines (DHHS 2018; WHO
2016 and 2018; and PENTA 2015),7,20–22 and the studies that
are used to inform these recommendations. For these studies,
we extracted the following PK parameters: area under the
concentration–time curve (AUC), plasma trough concen-
trations (Ctrough), and maximum plasma concentration (Cmax),
as well as the characteristics of the studied populations.
A PubMed search was used to explore the available
data on ARV dosing using the combined strategy with the key
words and MeSH terms for generic names of the currently
used ARV drugs and ARV classes, HIV infection, PK, and
TDM (see Search strategy, Supplemental Digital Content
1, http://links.lww.com/TDM/A325 section of this review).
The search was restricted to the literature published in English
with no limits on publishing date. In addition, documentation
publicly available through the EMA and FDA was screened
and studies referenced by the above guidelines. Papers con-
taining data on the AUC, Ctrough, or Cmax of currently used
ARVs were considered and summarized. Trials with a median
or mean age of participants 18 years or older were not
included, except for reference information.
Dosing of ARVs in Children
ARV drug dosing currently recommended in children is
based on varying amounts of published data. In this section,
we describe individual ARVs (divided by drug class), provide
an overview of pediatric PK studies and dosing strategies in
children, and compare the PK parameters of the pediatric
studies with adult targets for therapeutic drug concentrations.
Dosing recommendations for the currently used pedi-
atric ARV drugs are presented in Supplemental Digital Con-
tent 2 (see Table 1, http://links.lww.com/TDM/A324).
NRTIs
A dual NRTI “back-bone” remains a key component of
current ARV regimens. NRTIs are prodrugs that are activated
intracellularly to exert their therapeutic effect. The NRTIs
presently used are abacavir (ABC), zidovudine (ZDV), lam-
ivudine (3TC), emtricitabine (FTC), tenofovir disoproxil
fumarate (TDF), and tenofovir alafenamide fumarate (TAF).
Although intracellular concentrations of some NRTIs were
shown to be correlated with markers of therapeutic effective-
ness, such as viral load decline and CD4 increase,25 measur-
ing intracellular concentrations of the active compound is
expensive and labor intensive, and thus, these concentrations
are not routinely targeted for TDM, except for research pur-
poses. Unfortunately, dose or plasma concentration of the
parent compound does not correlate well with intracellular
concentration of the active form of the drug at the target
site.26–28 The dose of an NRTI does not correlate with a PK
parameter that can predict efficacy; therefore, discussing the
dose of NRTIs is not within the scope of this review.
One exception is made for the new NRTI “TAF,” which
is expected to be more widely included in upcoming treat-
ment guidelines for children. Data on TAF are described in
relation to the InSTI elvitegravir below. NRTI-approved
doses are reported in Supplemental Digital Content 2 (see
Table 1, http://links.lww.com/TDM/A324) to provide a full
overview of dosing in the current guidelines.
NNRTIs
Efavirenz
Historically, efavirenz (EFV) has been dosed in adults
at 600 mg once daily (QD) with a backbone of 2 NRTIs,
although a lower 400-mg QD dose is now also recommended.
A target therapeutic range for mid-dose EFV levels of
.1.0 mg/L to ,4.0 mg/L has been identified in adult studies.
Half (50%) of adults with mid-dose levels under 1.0 mg/L expe-
rienced viral failure, whereas central nervous system side effects
increased about 3-fold with EFV plasma above 4.0 mg/L.29,30
EFV for children has been formulated as an oral
solution (30 mg/mL) or in capsules, which can be opened
to deliver an adjusted dose. Bioavailability of the oral liquid
relative to capsules or tablets is low at only 46.6% and has
also shown to give more variable exposure. The liquid
formulation is not part of the ARV guidelines anymore.31,32
EFV is licensed by the EMA and FDA for children
aged 3 months and older weighing more than 3.5 kg and is
dosed based on weight bands (see Table 1, Supplemental
Digital Content 2, http://links.lww.com/TDM/A324). Never-
theless, guidelines do not recommend the use of EFV in
children younger than 3 years because of highly variable
PK in young children. EFV is primarily metabolized by the
cytochrome-(CYP)2B6 enzyme and EFV PK is affected by
polymorphisms in the CYP2B6 gene. The International
Maternal Pediatric Adolescents AIDS Clinical Trials Network
(IMPAACT) P1070 trial showed considerable risk of under-
dosing in 80% of infants and young children who were
“extensive” metabolizers for CYP2B6. Alternatively, an
increased dose of EFV (approximately 1600 mg · [weight
in kg/70]) aimed to achieve adequate exposure for all partic-
ipants in the P1070 trial, led to approximately 4-fold
higher EFV exposure in the remaining 19% who were poor
metabolizers, and increased their risk of experiencing
EFV-associated side effects.33 Genetic polymorphism in other
EFV-metabolizing CYP enzymes, such as CYP2A6, has also
shown to affect EFV PK and could potentially influence treat-
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ment outcome in children.34,35 It is not recommended to treat
children younger than 3 years with EFV without CYP2B6
genotyping to guide dosing. Genotyping of CYP2B6 in older
children could possibly be beneficial to evaluate the necessity
for dose adjustment and to help decrease the risk of side
effects and incidence of viral failure.31,36 However, genotyp-
ing is expensive and most importantly not accessible to many
clinics, in particular in LMICs, and it is rarely used in clinical
practice.
Nevirapine
Despite the current global efforts to move away from
nevirapine (NVP) and the desire to transition to more optimal
and effective regimens, it has long been a core ARV in ART
regimens in some LMICs. In adults, NVP can be administered
as 200-mg tablets twice daily (BD) or 400-mg extended-
release (NVP-ER) tablets QD. NVP is both a substrate and an
inducer of the hepatic enzymes CYP3A4/5 and CYP2B6. To
allow for autoinduction to set in, a 2-week lead-in dos of 50%
of the therapeutic dose is used in adults, and this concept is
also still recommended for pediatric dosing in the United
States and Europe (except for neonates where no lead-in is
required).20,37
In the presence of replicating virus, a single mutation
can select for high-level resistant virus to NVP, and several
studies have found association between low NVP concen-
trations and virological failure; therefore, achieving and
maintaining therapeutic drug levels of NVP is crucial.38 Dif-
ferent target plasma trough concentrations have been identi-
fied in adults ranging from 3.0 mg/L39 to 4.3 mg/L.40,41 The
most commonly followed target is a Ctrough of 3.0 mg/L, as
this threshold was derived within the largest cohort.39 No
direct relationship was found between NVP PK parameters
and NVP-associated toxicity: higher NVP concentrations are
not strongly related to increased incidences of adverse events
such as rash or hypersensitivity.42
The Verve study showed an increase in viral failure with
Ctrough levels,2.0 mg/L in adults treated with NVP-ER; there-
fore, NVP plasma levels of 2.0 mg/L can be considered a target
for treating patients with NVP-ER administered QD.43
Once-daily dosing with extended-release NVP formu-
lation is licensed in children older than 6 years after a lead-in
period with a 50% dose using formulations meant for BD
dosing. Giaquinto et al44 studied the PK of the extended-
release formulation in pediatric patients and showed that the
median AUC and Ctrough are comparable with the immediate-
release NVP formulation.
NVP is used in children either as a prophylactic agent,
in the context of perinatal transmission prevention, or for
treatment. As a prophylactic agent, different dosing strategies
are used with similar efficacy.45,46 These regimens were orig-
inally designed to maintain NVP plasma concentration .0.1
mg/L throughout the period at risk of HIV exposure.47
Several immediate-release NVP formulations are
licensed for treatment in children and they are all considered
to be bioequivalent.37 Although DHHS guidelines recom-
mend giving NVP from birth (without the lead-in period), it
is not approved for newborns younger than 15 days of life
according to the current FDA-approved package insert. The
current NVP dose in children is based on scaled-down adult
doses. Both the EMA and FDA recommend NVP in children
dosed 150 mg/m2 BD with a lead-in dose of 150 mg/m2 QD
for 2 weeks. Dosing guidance by the WHO is based on
weight bands. A modeling study by Nikanjam et al,48 based
on combined NVP PK data from a range of pediatric studies,
demonstrated that WHO weight-band dosing would maintain
adequate drug levels for the majority of patients similar to the
FDA BSA–based dosing schedule.
Gopalan et al (the study in children 2 to,18 years) and
Fillekes et al (the study in children .1 month old weighing 3
to ,6 kg) found subtherapeutic NVP concentrations in up to
65% and 32% of their respective study populations in the
lead-in period (see Table 2, Supplemental Digital Content
2, http://links.lww.com/TDM/A324).38,49 In addition, starting
with the full dose did not translate to increased adverse events
in these studies.38,49 This information is likely to change
recommendations regarding NVP lead-in dosing in the guide-
lines. Predicting NVP oral clearance is even more difficult
because of the impact of genotypic polymorphism in the
CYP450 enzymes involved in the metabolism of NVP. For
example, CYP2B6 polymorphism affects clinical outcomes in
children. Children with the “extensive” metabolizer pheno-
type have an increased risk of being underdosed.50
Rilpivirine
Rilpivirine (RPV) dosed 25 mg QD is used, mostly in
Western countries, as part of triple therapy with dual NRTIs
in adults and adolescents. It is also increasingly used in
combination with other ARV classes and as a part of dual
therapy including oral and long-term injectable formulations
(DTG + RPV or cabotegravir [CAB] + RPV). In combination
with NRTIs, RPV should only be used in patients with initial
viral loads ,100,000 copies/mL. With higher initial viral
loads, RPV-based ART had higher rates of virological failure
compared with EFV-based ART.51
Target therapeutic plasma trough concentration for
RPV has not been clearly defined, but lower rates of
virological response have been found with median Ctrough
concentrations below 0.042 mg/L.52 In terms of toxicity,
RPV increases QT interval in a concentration-dependent man-
ner. Clinical relevant increases in QT have been correlated
with Cmax concentrations .0.60 mg/L.52,53
Adult doses of RPV is approved by the EMA and FDA
to use for children older than 12 years and weighing more than
35 kg with viral loads ,100,000 copies/mL. In the PAINT
study, 4 of 8 (50%) participants aged 12 to ,18 years with
initial viral loads.100,000 copies/mL did not meet virological
suppression criteria versus 6 of 28 (79%) participants with
initial viral loads ,100,000 copies/mL, supporting the validity
of this virologic cutoff in children (see Table 2, Supplemental
Digital Content 2, http://links.lww.com/TDM/A324).54
In children aged 12–18 years, the PK parameters of RPV
were similar to adults with comparable variability. The studies
in adolescents did not report a correlation between dose and
efficacy or toxicity. There have been no studies published yet
using a pediatric RPV formulation. Further research on RPV
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formulations including long-acting injectable formulations in
children and adolescents is needed to guide dosing in younger
children and to evaluate targets for therapy.
PIs
Atazanavir
Atazanavir (ATV) is dosed in adults QD either in
combination with PK “boosters” ritonavir or cobicistat at
300/100 mg and 300/150 mg, respectively, or unboosted
under restrictive conditions 400-mg ATV QD, combined
with a NRTI back bone.
ATV drug monitoring is guided by trough concen-
trations. Trough concentrations of ATV above 0.15 mg/L are
correlated with lower rates of viral failure in ART-naive
patients.55,56 Patients previously treated with PI containing
ART need higher ATV trough levels for each mutation that
decreases the susceptibility of the virus to ATV. A concen-
tration of 0.23 mg/L/mutation has been correlated with higher
efficacy.57 The upper limit of treatment dose is less well
defined but is determined by the rise of unconjugated biliru-
bin, the main adverse event caused by ATV, for which a cor-
relation is seen with ATV Ctrough in the range of 0.50–0.76
mg/L.58–60 Safety data from a large cohort study on ATV/r in
children also show increasing incidence and severity of hy-
perbilirubinemia with increasing Ctrough.61 Because in this
case the increase in bilirubin is not a product of liver damage
but rather because ATV interacts with bilirubin conjugation,
this effect is benign. Advantages of therapy should be
weighed against potential stigmatizing side effect of icteric
eyes from an increase in unconjugated bilirubin.
In children, ATV is administered only as ATV/r and is
recommended for children older than 3 months weighing .5
kg following the dosing schedule displayed in Supplemental
Digital Content 2 (see Table 1, http://links.lww.com/TDM/
A324). ATV boosted with cobicistat has not been studied in
children. Under 3 months of age, the risk of ATV-induced
kernicterus increases, and ATV is thus not recommended in
this age group. In a pediatric ATV dose-finding study
(IMPAACT P1020; n = 195 children aged 3 months to 21
years of age), Kiser et al62 aimed to attain ATV PK param-
eters similar to adults. They used a range of increasing ATV
doses over an increasing range of the BSA, both with and
without ritonavir boosting, and attained the target PK param-
eters with ATV/r for children across all studied age groups,
and with unboosted ATV capsules for children 2 to ,13
years. However, treatment with unboosted ATV powder for-
mulation could not satisfy predetermined PK parameters in
children aged 3 months to ,13 years. This was likely a con-
sequence of low ATV bioavailability, a faster clearance, and
a wide intersubject variability in this age group.62,63 Subse-
quent modeling by Hong et al64 translated dosing based on
the BSA into a dosing table based on weight bands for the
capsule formulations. The PRINCE I and PRINCE II trials
showed that ATV powder formulation in combination with
RTV liquid in children 3 months to ,11 years and weighing
5 to ,35 kg dosed in weight bands reached the target drug
exposure levels.61,65,66 Results from the PRINCE I and II
trials together with IMPAACT P1020 and the modeling study
by Hong et al supported the FDA approval of ATV/r doses in
children (see Table 3, Supplemental Digital Content 2,
http://links.lww.com/TDM/A324).
Two additional studies with ATV/r in children are
referenced in Supplemental Digital Content 1 (see Table 3,
http://links.lww.com/TDM/A324). One study investigated the
dosing of ATV/r combined with TDF in Asian children living
with HIV.67 It is hypothesized that TDF decreases ATV expo-
sure by inducing P-glycoprotein, resulting in decreased ATV
bioavailability.68 Higher PI drug levels have been reported in
people of Asian origin.69 Bunupuradah et al67 showed that
200-mg ATV boosted with 100 mg of ritonavir within a reg-
imen containing TDF was able to achieve ATV levels com-
parable with adult levels in Asian children aged 6–18 years.
Another study, by Cressey et al,70 investigated the possibility
of using unboosted ATV in ART-experienced Thai children
unable to take ritonavir. Doses of 400-mg and 600-mg un-
boosted ATV did not achieve target Ctrough levels and were
highly variable between patients. Theoretically, increasing the
unboosted ATV doses further may be able to exert sufficient
exposure, but this requires additional research.
The results from pediatric ATV trials displayed in Sup-
plemental Digital Content 2 (see Table 3, http://links.lww.
com/TDM/A324) show the data used to inform the decision
on ATV doses for the product label and in the current guide-
lines. It should be noted that weight-band pediatric doses are
derived from doses based on the BSA in the P1020 trial and
converted to weight-band dosing by modeling alone (Hong
et al64). Thus, clinical validation of these doses is needed,
which is planned in the CHAPAS-4 trial.71
Two separate ATV formulations are used in children:
oral powder and capsules. According to the regulatory
agencies, the formulations are not bioequivalent based on
results of the Prince I and Prince II studies, and according to
a modeling study by Hong et al, who report a modeled relative
bioavailability decrease of 35% for oral powder formulation
compared with the capsule formulation for children 15–25
kg.72 This assumption is not supported by the findings from
the IMPAACT P1020 trial, who show that a 150% increase of
mg/m2 dose in capsule versus oral powder resulted in
a .150% increase in Ctrough.62 In the IMPAACT trial, these
formulations result in similar exposure. However, the age and
weight of these children was different between the groups.
Darunavir
In adult patients, darunavir/ritonavir (DRV/r) is dosed
at 800/100 mg QD in treatment-naive or treatment-
experienced patients without genotypic resistance to daruna-
vir and 600/100 mg BD in patients with DRV-specific
mutations.
No relation to clinical effect has been reported for DRV
AUC or Ctrough values, but an in vitro study by Kakuda et al73
showed that a protein-binding adjusted plasma concentration of
0.55 mg/L exerts 50% of the maximal effect (EC50) for sus-
ceptible viruses. No EC90 or other efficacy parameters have
been reported. Mean Ctrough for QD DRV/r in adults was 2.0
mg/L.73 Interestingly, 50% reduced Ctrough did not lower the
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predicted mean virological response rate in the ARTEMIS trial
(92.8% for .2.0 mg/L versus 93% for .1.0 mg/L), showing
that a Ctrough of 1.0 mg/L can also be adequate.
Darunavir is licensed in children older than 3 years
weighing more than 10 kg. Boosted with ritonavir, it can be
dosed BD or QD. Boosting DRV with cobicistat has not been
studied in children and is therefore not approved by the EMA
or FDA. There are multiple DRV formulations available for
pediatric dosing, all considered to be bioequivalent.74 A sus-
pension of 100 mg/mL can be used in children from 10 kg;
for children over 15 kg able to swallow tablets, tablets are
available. Both the FDA and EMA approved QD dosing for
children without DRV resistance–associated mutations, and
BD dosing for children with DRV mutations. PENTA 2015
and DHHS guidelines recommend BD dosing for all children
,40 kg (see Table 1, Supplemental Digital Content 2,
http://links.lww.com/TDM/A324).
Pediatric Dosing of BD Darunavir Ritonavir
A series of trials investigated DRV dosing in children in
a stepwise approach down to age of 3 years. The Delphi study
investigated DRV/r BD in children 6 years or older. Stratified
by weight bands, pediatric patients reached PK parameters
comparable with results achieved in adult studies. Initially,
a dose directly scaled down from adults was studied, but this
was rejected because of inferior exposure.75 The age limit for
DRV use was lowered to 3 years based on the ARIEL study.
In ARIEL, children older than 3 years and weighing .10 kg
were initially dosed 20/3 mg/kg. This dose was increased to
25/3 mg/kg for children 10 to ,15 kg and a fixed dose of
375/50 mg/kg was given to children 15 kg to,20 kg because
low AUC0-24 and Ctrough were projected by a modeling study
and after reviewing the week 2 safety, PK, and antiviral
activity data within ARIEL. Subsequent PK analysis of the
new dose revealed increased AUC0–24 and Ctrough levels com-
pared with adult parameters.76 However, no adverse events
were reported when the dose was increased to 25/3 mg/kg in
the ARIEL trial.77 Eventually, FDA reviewers recommended
the initial dose of 20/3 mg/kg DRV/r for children 10 to
,15 kg.76,77 This decision was based on 2 considerations
(1) additional analysis of the data from the ARIEL trial
showed that the exposure reached with a dose of 25/3
mg/kg DRV/r was 153% of the adult exposure; and (2)
administering a dose requires an oral syringe to obtain the
required volume, which is prone to mistakes and poses addi-
tional risk of high exposures. Ultimately, this means that the
current FDA-licensed dose for children 10 to ,15 kg is based
only on 2 weeks of PK and safety data before the dose was
increased in the ARIEL trial. The WHO recommends a dose
of 250-mg DRV for children 10–14.9 kg (25 –16.67 mg/kg)
based on modeling.78 The EMA currently has not licensed
dosing in children weighing ,15 kg.
Pediatric Dosing of QD Darunavir Ritonavir
Once-daily dosing in pediatric patients has been
explored in several studies (see Table 3, Supplemental Dig-
ital Content 2, http://links.lww.com/TDM/A324). QD dosing
of DRV/r in children is largely based on the ARIEL study for
3 to ,6 years old, and the DIONE study for 12 to ,18-year-
old children. Using these data, Brochot et al79 modeled dos-
ing for children 3 to ,12 years old and provided the dosing
recommendations for children 6 to ,12 years old. However,
the following Daphne trial reported a geometric mean AUC of
only 70% of the adult levels with the suggested doses in
children 12 to ,18 years old.80 Despite the lower exposures,
the authors argued that the children were adequately treated
given the high viral suppression rates (91% at 12 months)
observed in this study and the fact that all observed Ctrough
values were well above EC50 for susceptible viruses, which
could be considered a target level for therapy.
It must be noted that all patients in the pediatric trials of
QD DRV, except in the study by Chokephaibulkit et al, had
a Ctrough above 0.55 mg/L, the EC50 for susceptible viruses
(see Table 3, Supplemental Digital Content 2, http://links.
lww.com/TDM/A324),81 and all children had high viral sup-
pression rates regardless of decreased AUC compared with
adult AUC.75,76,80,82,83
Lopinavir/Ritonavir
Lopinavir/ritonavir (LPV/r) dosed 400/100 mg BD
combined with 2 NRTIs can be used in adult treatment. In
treatment-naive adults or adults with less than 3 relevant PI
mutations, a QD regimen of LPV/r combined with an NRTI
backbone can be used at 800/100 mg.
Lopinavir Ctrough of 1.0 mg/L has been shown to give
sufficient LPV exposure in ART-naive patients, and this level
is used as a target for TDM in both adult and pediatric patients.7,84
For ART-experienced patients, target trough concentrations are
related to the number of mutations and are reported varying from
0.7 to 0.9 mg/L per LPV-relevant mutation.85,86 Some studies
have been conducted to determine whether the target trough level
for adults can be used in pediatric therapy, but no different target
has been adopted so far for treating children.87–89
Lopinavir/r is licensed for use in children from the age
of 14 days. Owing to cardiac and metabolic toxicities as well
as risk of adrenal insufficiency, children younger than 14 days
should not use LPV/r.18
Lopinavir can be administered as liquid formulation or
pediatric tablets (for children .15 kg). The tablet formula-
tion has shown less variability than the previously used
softgel capsules.69,90 Dosing on the BSA requires calcula-
tion. To make dosing easier, weight-band–based dosing was
explored by Bastiaans et al.91
Both 230/57.5 mg/m2 and 300/75 mg/m2 LPV/r doses
are within the recommendations of the DHHS guideline and
have shown adequate efficacy and acceptable toxicity in tri-
als.92–98 However, concerns have been raised on the durabil-
ity of the levels of exposures achieved by the 230/57.5 mg/m2
dose, especially in children,2 years old, for whom increased
LPV clearance is observed.99–101 Because of these concerns,
300/75 LPV/r mg/m2 dose is recommended for treatment-
experienced children of all ages; 230/57.5 mg/m2 can be used
in treatment-naive children aged .1 year.
Furthermore, Rakhmanina et al102 concluded that the
current BD LPV/r dosing strategy for naive children appears
to be adequate for therapy in children infected by wild-type
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virus but is unlikely to be suppressive for viruses with even
mild resistance to LPV. The authors conclude that patients
would benefit from TDM and resistance testing.
Once-daily dosing of LPV is not recommended in
routine care of HIV-infected children. Although LPV expo-
sure of QD LPV/r is comparable with exposures seen in
adults, noninferiority of LPV/r QD was not proven to the BD
regimen in a randomized controlled trial.103–105 The KON-
CERT trial compared LPV/r dosed QD versus dosing BD in
virologically suppressed children and reported a doubling in
risk of viral failure when using a QD regimen versus the
conventional BD regimen. This result appears to be primarily
influenced by nonadherence and showed that a QD dosing
strategy was less forgiving than the BD standard regimen.
However, in a select group of adherent children and under
guidance of TDM, QD dosing of LPV/r can be a valid
treatment.106
A recent modeling study evaluated the effect of formu-
lation and age on the exposure of LPV. A dramatic decrease in
relative clearance with increasing age was noted in the first 2
years of life, and an increase in bioavailability was observed
when children were switched from liquid formulation to tablet
formulation, providing evidence for the need to re-evaluate
current dosing of LPV in young children or perhaps change to
a different formulation such as LPV/r oral pellets.107 LPV/r
oral pellets have shown to increase exposure compared with
the liquid LPV/r formulation in children in the CHAPAS-2 trial
and were associated with high levels of viral suppression in the
LIVING study.108,109 These oral pellets are currently approved
by the WHO and the FDA under the PEPFAR program.110,111
A novel pediatric LPV/r granule formulation is now available
(40/10 mg) and actively introduced in countries while a taste-
masked LPV/r granule formulation within a fixed-dose
combination (FDC) with abacavir/lamivudine (4-in-1 combina-
tion) is being finalized with anticipated approval in early 2020.
InSTIs
Dolutegravir
Dolutegravir (DTG) has been at the center of attention
lately because of its excellent viral outcomes, high barrier to
resistance, broad therapeutic window, and relatively few drug
interactions compared with PIs. DTG in adults is dosed at 50
mg QD when InSTI-naive and can be increased to 50 mg BD
when InSTI resistance–related mutations are present. It is
available as single strength tablets and in FDCs with ABC/
3TC or TAF/FTC.
There is no consensus on the PK target related to
efficacy for DTG. Ctrough best predicted plasma viral load
reduction in a 10-day DTG monotherapy study by Min
et al.112 The Emax model identified an EC50 of 0.036 mg/L
and calculated EC90 of 0.324 mg/L, the latter could be taken
as a cutoff for efficacy.112 Safety data do not show a relation-
ship with PK targets.
In children, DTG is dosed according to Supplemental
Digital Content 2 (see Table 1, http://links.lww.com/TDM/
A324) and is licensed in Europe for children older than 6 years
and 15 kg. Currently, the approved dose can be delivered
using a film-coated tablet in 2 dosage forms (10 and 25
mg), and work is undergoing to test a dispersible 5-mg tablet
for dosing in younger children as well as a FDC in combina-
tion with ABC/3TC.
The IMPAACT P1093 trial is an ongoing dose-finding
study, evaluating the safety of DTG in children down to 4
weeks of age. Based on data from P1093, the adult dose is
approved by the EMA and FDA for ART-naive and ART-
experienced—but InSTI-naive—children older than 6 years
weighing over 40 kg. A decreased dose of 35 mg QD is
approved for children 30 to ,40 kg. The EMA has also
approved dosing in children older than 6 years weighing
.15 kg, based on a modeling study by Sing et al informed
by data from the IMPAACT P1093 trial.113 However, the
FDA concluded that the data for the lowest weight bands
were insufficient to recommend the use of DTG in children
,30 kg because of the scarcity of the data and lower than
expected observed Ctrough.
Recently, new PK information on DTG in children has
become available from P1093 and ODYSSEY trials. In
a nested PK study within the ODYSSEY trial aiming to
simplify the dosing across the WHO weight bands, children
14 to ,25 kg were dosed at 25 mg (steady-state intensive
single PK curve), whereas children 25 to ,40 kg had a cross-
over PK assessment and received a licensed dose on the first
PK day and an adult dose of 50 mg on the second PK day.
Participants 14 to ,25 kg and 25 to ,40 kg on the initial
doses (PK day 1) showed lower Ctrough levels compared with
adults. However, with the increased dose of 50-mg DTG, the
Ctrough levels in children 25–40 kg increased comparable with
adult reference values. Based on these results, the WHO rec-
ommended a DTG dose of 50 mg for children $25 kg in the
revised guidelines. PK data from the Odyssey trial in children
20 to,25 kg treated with 50-mg film-coated tablets or 30-mg
dispersible tablets showed exposures and trough levels com-
parable with adult data but with Cmax exceeding adult refer-
ence values. Doses intended to achieve higher plasma drug
levels are currently being investigated with both dispersible
and film-coated tablets in younger children in the ongoing PK
study in ODYSSEY.114 Both ODYSSEY and P1093 have
started enrolling children from 4 weeks; some available data
are presented in Supplemental Digital Content 2 (see Table
4, http://links.lww.com/TDM/A324).
Raltegravir
Raltegravir (RTG) shows good therapeutic efficacy in
adults at a dose of 400 mg BD or 1200 mg RTG high-dose
(two 600-mg tablets) QD.
PK targets are devised based on a number of studies
with QD dosing of RTG in adults but could not be identified
in studies using the registered BD dose. Ctrough concentrations
below 0.045 mg/L correlated with increased viral failure.115
Correlations between plasma concentrations and toxicity have
not been reported to date.
RTG can be used in children across all ages. Different
formulations of RTG have been approved by the EMA and
FDA. RTG weight-band dosing is available for children from 2
kg using granules for oral suspension, before moving on to
Ther Drug Monit  Volume 41, Number 4, August 2019 Optimizing Pediatric Dosing Recommendations
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of
Therapeutic Drug Monitoring and Clinical Toxicology. 437
pediatric chewable tablets for children weighing $11 kg and
film-coated tablets for children $25 kg (see Table 1, Supple-
mental Digital Content 2, http://links.lww.com/TDM/A324).
Oral suspension has shown better oral bioavailability compared
with the chewable tablets, and both formulations showed
greater bioavailability compared with the film-coated tablets.116
All formulations should be dosed according to their own spe-
cific dosing guidance as displayed in Supplemental Digital
Content 2 (see Table 1, http://links.lww.com/TDM/A324).116
In the pediatric trials (see Table 4, Supplemental Dig-
ital Content 2, http://links.lww.com/TDM/A324), the tested
dosing showed mean PK parameters comparable with adult
values. However, large variability in PK parameters was
observed when treating children, especially with the film-
coated tablets. For patients younger than 6 years, the coeffi-
cient of variation was over 200%. RTG doses for children
aged 4 weeks to ,18 years old were confirmed in a modeling
study using the data from the P1066 trial.117 In this study, all
dosing strategies met the prerequisite PK targets. Recently,
data of RTG oral granules for suspension were presented
showing RTG was safe and well tolerated during the first 6
weeks of life, although a complex preparation process and
increasing RTG doses to accommodate for rapidly increasing
UGT1A1 metabolism is required in the neonatal period.118
Feasibility and acceptability studies are required to evaluate
the utility of these formulations in remote settings.
Pediatric RTG dosing is currently based on PK data
from a limited number of children with large variability.
These data are backed up with a modeling study based on the
data from the same trial. Taking into account that therapeutic
targets are not yet very well defined, larger and more variable
cohorts should be studied to know whether these dosing
guidelines ensure efficacy in children. Only about 50% of
children in the P1066 trial reached a viral load of,50 copies/
mL and over 70% of subjects had viral load of ,400 copies/
mL at 48 weeks of therapy. This difference indicates low-
level viremia in some children, whether this has led to the
development of resistance in these trials, has not been yet
reported.119,120 Overall, taking into account, BD dosing and
low barrier to resistance RAL does not appear to be the best
option for older children and adolescents. However, in view
of the limited ART regimens for neonates and young children,
RAL presents an important treatment option while we await
dolutegravir to become available for this age group.
Elvitegravir
Elvitegravir (EVG) is dosed in adults only as part of
FDC tablets that include the PK enhancer cobicistat. FDC
tablets include 150-mg EVG coformulated with COBI 150
mg plus FTC 200 mg, and either TAF 10 mg or TDF 300 mg.
A target for therapy was identified based on the initial
dose-finding studies by DeJesus et al.121 A Ctrough value of
0.13 mg/L showed an almost maximum effect based on an
Emax model. There was no target identifiable that showed
correlation with any toxicity markers.
Recently, studies have indicated that EVG can be used
in children older than 6 years and weighing at least 25 kg
combined with COBI and TAF/FTC at adult doses. In
combination with TDF/FTC, EVG/COBI is only approved
by the EMA and FDA for children older than 12 years.
There are 2 studies on PK of EVG in children reported in
Supplemental Digital Content 2 (see Table 4, http://links.lww.
com/TDM/A324).122 For both groups, but especially in children
6–11 years old, the AUC, Cmax, and Ctrough concentrations are
higher than in the adult population. Moreover, trough concen-
trations for these children show considerable variability for both
children 6–11 years old and 12 to ,18 years old. Long-term
safety of this combination in children still needs to be examined.
Currently, only the adult fixed-dose formulations EVG/TAF/
FTC and EVG/TDF/FTC have been studied in children, the
latter one in children older than 12 years. This leaves little
flexibility in adjusting doses for pediatric populations.
TAF in FDC Therapy
PK data for TAF in children have been reported
simultaneously with data from EVG when the coformulated
product was studied and is therefore included in this review.
Just like TDF, TAF is a prodrug of tenofovir, but compared
with TDF, TAF attains 90% lower circulating plasma
concentrations of tenofovir.123,124 Intracellular levels are
however increased 2.4-fold when using TAF.124 TAF has
shown to be promising for use in children as, unlike TDF,
it is not associated with side effects related to decreasing bone
mineral density and renal tube defects.125,126
For treatment of HIV infection, TAF is currently
available only in adult FDCs: FTC/TAF 200/25 mg, EVG/
COBI/FTC/TAF 150/150/200/10 mg, and RIL/FTC/TAF 25/
200/25 mg.
TAF is dosed 25 mg QD when used in FDCs without
a booster (approved by the EMA and FDA in children $25
kg) and 10 mg QD when combined with a boosted PI or
cobicistat (approved from 35 kg). The FDA has also approved
using FTC/TAF 200/25 mg in combination with other ARV
drugs (irrespective of the boosting effect of the third agent) in
adults and adolescents $35 kg. With TAF, safety or efficacy
is not related to plasma PK end points in adults or children.
In the 2 studies with TAF in children, safety and
efficacy were comparable with adult data, although plasma
AUC was 171% relative to adult AUC for children between 6
and 11 years old. Intracellular levels will need to be examined
in children to relate dose to effect.
General Discussion and the Role of TDM
To the best of our knowledge, this is the first
comprehensive review of the currently FDA- or EMA-
approved and recommended pediatric ARV dosing and the
evidence that informed these dosing recommendations.
Current dosing recommendations for children are not always
homogenous between international regulatory agencies and
HIV management guidelines. Often, dosing of pediatric ART
is based on small studies, and sometimes due to the location
of the study among children from similar ethnic populations.
Differences in metabolizing enzyme activity between ethnic-
ities can result in differences in ARV PK in children. For
instance, with the standard recommended dose, African
children with lower CYP2B6 activity have an increased
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chance of high EFV exposure, and Asian children are more
likely to have high plasma ATV exposure because of the
lower UGT enzymatic activity.127
PK models derived from small sample sizes of a hetero-
geneous population are essential to speedup drug investigation,
approval, and use of novel ARVs, as they become available but
carry the risk of covariate–parameter relationship mis-
specification, and subsequent extrapolation to other pop-
ulations resulting in potential suboptimal doses.128 A recently
approved DTG dose for children below 40 kg and DRV/r QD
dosing for children 6 to ,12 years old are examples of mod-
eled doses, which subsequently did not reach PK targets in PK
studies. PK parameters in pediatric dosing studies have high
variability, indicating uncertainty on how many children are
exposed to inadequate drug levels. This highlights that post-
marketing collection of TDM data, where feasible, could be
helpful to validate model-based dosing strategies and inform
dose adjustments where required.
In an effort to streamline the search for appropriate
pediatric ART dosing and formulations, the WHO and
UNITAID have recently developed the “Toolkit For Research
And Development Of Pediatric Antiretroviral Drugs And For-
mulations,” in which recommendations are made on how
development of new pediatric ARV formulations and clinical
trials in children can be made faster and more efficient.10 Nev-
ertheless, the development and approval of pediatric ARV for-
mulations and pediatric dosing remains a lengthy process. To
accelerate the development of pediatric formulations, efficacy
should be extrapolated from adult trials provided the PK targets
can be achieved, staggered age/weight-cohort enrollment
design should be avoided, and adolescents should be enrolled
in adult trials because all drug development studies in adoles-
cents so far resulted in comparable plasma exposures, efficacy,
and safety to adults.10 Because weight-band dosing is now the
preferred approach, this type of dosing should be studied up-
front and included in the pediatric development plans with
subsequent validation in clinical practice. The latter is particu-
larly needed when a wide variation in PK is expected and the
dose might not achieve target drug levels in all children.
It is important to know the grounds on which a dose is
based to be able to evaluate the safety and to predict the
efficacy of the used dosing without guidance of drug levels in
the patient. TDM of ART is not recommended for routine
clinical care. Moreover, even for resource-rich setting, the costs
of implementing TDM to support clinical case management are
high (ie, initial outlay for installation of analytical equipment
and continued costs for maintenance), and often, there is a lack
of expertise to interpret the results. Measuring plasma levels of
ARVs also requires an acceptable turnaround time in order for
the results to have a clinical impact. Such requirements might
be problematic for facilities with limited resources and low
numbers of patients in care. There are proposed drug
concentration targets for certain ARVs (adult targets are
summarized in Table 1), and when physicians are uncertain
these targets are being achieved, TDM could be useful to guide
clinical management. Such TDM data can then be used to
monitor and validate clinical dosing, particularly when con-
comitant medication with known drug–drug interactions could
be considered for drugs for which the dosing recommendations
are based on insufficient data or little experience in practice.
Moreover, these TDM data can be critical to evaluate recom-
mended simplified dosing strategies proposed as part of a public
health approach. In this context, innovative methods for TDM
should also be explored to make TDM more affordable and
accessible in LMIC. Methods such as dried blood spots could
unlock TDM in countries where pediatric HIV is most
prevalent.129,130
Currently, no commercial assay has been developed for
the measurement of ARVs in plasma that has been approved
by the EMA or FDA. TDM methods are therefore developed
separately by each laboratory providing a TDM service for
ARVs, usually based on assay descriptions published in the
scientific literature. International interlaboratory quality con-
trol programs for measuring ARVs in plasma have been
established to guard the proficiency of these analytical
methods to be able to objectively validate the accuracy of
TDM results and enable the comparison of results between
labs.131,132 When carried out using the right criteria, TDM is
expected to improve individual patient outcomes and these
data could be used to help increase our knowledge of the
drug’s effectiveness within the wider pediatric population.
Therefore, TDM could be considered among the available
tools to inform our global efforts to optimize dosing for
children.
TABLE 1. Current Plasma Drug Targets for TDM of ARV Drugs
Drug Plasma Target Toxicity Considerations
NNRTI
Efavirenz (EFV) Mid-dose level $1 mg/L29 Mid-dose level ,4 mg/L30
Nevirapine (NVP) Ctrough $3.0 mg/L41 No relation found between PK parameters and toxicity
Rilpivirine (RPV) Ctrough $0.042 mg/L52,53 Cmax: ,0.60 mg/L52,53
PIs
Atazanavir (ATV) Ctrough $0.23 mg/L55,56 Ctrough: 0.50–0.76 mg/L58–60
Darunavir (DRV) Ctrough $0.55 mg/L73 No relation found between PK parameters and toxicity
Lopinavir (LPV) Ctrough $1.0 mg/L7,84 No relation found between PK parameters and toxicity
InSTI
Dolutegravir (DTG) Ctrough $0.324 mg/L112 No relation found between PK parameters and toxicity
Raltegravir (RTG) Ctrough $0.045 mg/L115 No relation found between PK parameters and toxicity
Elvitegravir (EVG) Ctrough $0.13121 No relation found between PK parameters and toxicity
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Table 1 summarizes PK targets for the ARVs discussed
in this review.
Limitations of this study are the inclusion of the
literature written in English only and search with a single
medical literature electronic database (PubMed), which could
result in missing other PK data in children from studies not
available on PubMed or not published in English.
CONCLUSION
This review summarizes the PK data available for
ARVs in children. The information on which licensing and
dosing guidelines are based is not as solid as might be
perceived from viewing the drug labels or the dosing guide-
lines without a closer look at the studies from which the doses
in the guidelines are drawn-up. Defining dosing in children is
not without obstacles, and dosing of ARVs is actually more
informed than many other types of drugs used in children.
However, there are gaps in our current knowledge, which
require further monitoring and PK studies in subpopulations,
larger sample sizes where there is high interpatient variability
in the PK parameters, and postmarketing real-life studies to
confirm acceptability and safety. ARV concentration data
generated from TDM can support our joint efforts to develop
simplified safe and effective dosing of ARVs across the
pediatric age continuum in the context of a public health
approach.
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